3D Prediction of Patient-Specific Response
This is a prospective, non-randomized, observational registry study evaluating a
patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or
resected tumor tissue for assessing tissue response to therapy in patients with advanced
cancers, including ovarian cancer, high-grade gliomas, and high-grade rare tumors.